Biologics are targeted prescription medicines, usually given by infusion or injection, that block a specific step in the immune response behind ulcerative colitis (UC). For moderate to severe disease the American Gastroenterological Association (AGA) recommends several of them over no treatment, and in trials they raise remission rates and reduce colectomy and hospital use (Singh 2024). They also carry labeled infection and cancer warnings, and some people never respond. So "worth it" is a trade-off to weigh with your gastroenterologist, not a verdict anyone can hand you.
This guide lays out both columns with numbers: what biologics deliver (remission, steroid-free remission, fewer colectomies, quality of life), what they risk (infections, cancer, reactions), and what uncontrolled UC costs you, since staying on a weaker plan is a choice with its own risks. It is information, not advice about your treatment. We do not tell anyone to start, stop, switch or change a medicine, and nothing here ranks one drug above another for you. It leads with the US, because trial data and labels are US-regulated, with notes where other countries differ.
How effective are biologics for ulcerative colitis?
In the pivotal trials, biologics beat placebo on clinical remission, but the gaps are measured in tens of percentage points, not near-universal success. At one year, roughly 38% to 45% of people who had responded to induction were in remission on vedolizumab or ustekinumab, versus 16% to 24% on placebo. Many people in the trials did not reach remission at all.
Here is what the main trials reported, from their published abstracts:
| Drug (class) | Trial | Result vs placebo |
|---|---|---|
| Infliximab (anti-TNF) | ACT 1 | Clinical response at week 8: 69% (5 mg/kg) and 61% (10 mg/kg) vs 37%; at week 54: 45% and 44% vs 20% (Rutgeerts 2005) |
| Vedolizumab (anti-integrin) | GEMINI 1 | Response at week 6: 47.1% vs 25.5%; remission at week 52: 41.8% (every 8 weeks) vs 15.9% (Feagan 2013) |
| Ustekinumab (IL-12/23) | UNIFI | Remission at week 8: about 15.5% vs 5.3%; at week 44: 38.4% to 43.8% vs 24.0% (Sands 2019) |
| Adalimumab (anti-TNF) | ULTRA 2 | Remission at week 8: 16.5% vs 9.3%; at week 52: 17.3% vs 8.5% (Sandborn 2012) |
| Mirikizumab (IL-23) | LUCENT-1 | Remission at week 12: 24.2% vs 13.3% (D'Haens 2023) |
Three cautions keep these numbers honest. First, trials use different definitions and populations, so the table must not be read as a league table; the AGA grouped drugs into higher, intermediate and lower efficacy tiers using its own evidence review, not by eyeballing trial results (Singh 2024). Second, the maintenance figures only include people who responded to induction, which flatters the drug. Third, in ULTRA 2, people who had been treated with an anti-TNF before did worse, with week 52 remission of 10.2% versus 3% on placebo, against 22% versus 12.4% in people new to anti-TNFs (Sandborn 2012).
The ordinary reading is this: biologics shift the odds, often meaningfully, and they work best for people who respond early. They do not guarantee remission, and the first drug is not always the last. For what to expect from the first infusion, see what to expect at your first biologic infusion.
Do biologics give steroid-free remission?
They can, and steroid-free remission is a better yardstick than "feeling better," because steroids can mask active disease while causing harm of their own. In the SUCCESS trial, 39.7% of people on infliximab plus azathioprine were in steroid-free remission at 16 weeks, versus 22.1% on infliximab alone and 23.7% on azathioprine alone (Panaccione 2014).
Why this matters is clear in older population data. In a Minnesota cohort of people with UC treated with a first course of steroids, 54% reached complete remission within 30 days, but one year later 22% were steroid dependent and 29% had had an operation (Faubion 2001). That cohort was diagnosed between 1970 and 1993, before biologics, so it shows what the older pattern looked like, not what happens today. It still explains why guidelines treat steroids as a bridge, and why the reason to move to a longer-term medicine is often to get off them.
The AGA's own wording is cautious and worth knowing: for people who failed 5-aminosalicylates (mesalamine) and need to escalate, it suggests early use of advanced therapies or immunomodulators rather than a gradual step-up (Singh 2024). That is a statement about the pathway, not about what any individual should take. If you are still working out whether mesalamine is enough, what to take when mesalamine stops working walks through the ladder.
If you are still weighing how well mesalamine itself performs before this decision, does mesalamine work for ulcerative colitis sets out the remission and relapse numbers.
Do biologics reduce the chance of needing a colectomy?
Yes, but by a modest margin that the trials can quantify. In the infliximab ACT 1 and 2 trials, cumulative colectomy through 54 weeks was 10% with infliximab versus 17% with placebo, an absolute reduction of 7 percentage points. Hospitalizations for UC were also halved, from 40 to 20 per 100 patient-years (Sandborn 2009).
Zooming out, a 2023 systematic review of 31 studies and 294,359 people found colectomy in 3% of people with UC at 1 year, 5% at 5 years and 10% at 10 years after diagnosis. Colectomy rates have fallen over three decades, and the authors concluded that biologics may have contributed, though the relative reduction was likely modest (Dai 2023). The post-biologic era relative risk at one year was 0.68, but its confidence interval (0.42 to 1.09) crossed 1.
Two things are worth saying about this number. One, a lower colectomy rate is not the only goal, and surgery is sometimes the right answer rather than a failure; our guides on how to know if you need a colectomy and life after colectomy cover that decision honestly. Two, when UC becomes acute and severe, the numbers are stark: a pooled analysis of 32 studies found that 27% of people hospitalized with a severe attack needed a colectomy in the short term, and that this rate had not changed in 30 years (Turner 2007). Many of those studies predate current biologics, so it describes the risk of an uncontrolled flare, not the risk on treatment. If you ever have heavy bleeding, fever or severe pain, see when to go to the hospital for a UC flare.
What do biologics do for quality of life?
They can improve it substantially in the people who respond, and that is the outcome Reddit reports most. In the infliximab ACT trials, baseline scores showed substantial impairment in health-related quality of life, and infliximab improved the total IBDQ score more than placebo at week 8, a benefit that was sustained through one year on maintenance treatment (Feagan 2007).
The international treat-to-target consensus, STRIDE-II, agrees that this is not a soft outcome. It lists clinical remission and endoscopic healing as long-term targets and adds absence of disability and restoration of quality of life (Turner 2021). In other words, the specialists who set the goals for treatment count "can I live my life" as part of whether treatment is working.
This is where the lived experience in r/UlcerativeColitis lines up with the trial data. In the thread asking whether people regret biologics (more than 200 comments, Do you regret Biologics?), the most upvoted answers describe years of remission and getting daily life back, often after a long stretch of undertreatment. A smaller group describes the opposite: a drug that never controlled their symptoms, so the regret is about the drug failing, not about taking it. Read these threads as testimony, not odds, because people with strong feelings post and people with quiet success do not.
Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.
What are the risks of biologics for ulcerative colitis?
The labeled risks center on infections, a smaller set of cancer signals, and reactions to the drug itself. In trials, the overall picture is more reassuring than the warning boxes suggest, but registries and labels still show a measurable increase in infections, especially opportunistic ones. The point is to quantify them, not wave them away.
Infection. A network meta-analysis of 49 randomized trials with 14,590 participants found biologics modestly raised the risk of any infection (odds ratio 1.19) and of opportunistic infections (odds ratio 1.90), but did not raise the risk of serious infections (odds ratio 0.89; in studies at low risk of bias the odds ratio was 0.56) (Bonovas 2016). Randomized trials are short and select healthier people, so the real-world picture matters too. A Swedish nationwide cohort of people with Crohn's or UC found that serious infections were already more common in people with IBD who took no immunomodulator or advanced therapy (2.31 per 100 person-years, adjusted hazard ratio 1.89 against matched comparators whose rates ranged from 0.39 to 1.13). Rates were 3.14 to 8.10 per 100 person-years on advanced therapies, with no significant difference between the advanced therapies once patients were matched (Axelrad 2026). That cohort combines Crohn's and UC, and confounding by disease severity is hard to remove, so it cannot tell you that a biologic caused each infection. It does show that "infection risk" is partly a feature of having active IBD.
Cancer. The same meta-analysis found no increase in malignancy with biologics (odds ratio 0.90, 95% CI 0.54 to 1.50), but its authors said the data were insufficient in terms of exposure and follow-up time (Bonovas 2016). Lymphoma is the signal doctors discuss most. In a French cohort of 189,289 adults with IBD, lymphoma occurred at 0.26 per 1,000 person-years in people unexposed to thiopurines or anti-TNF drugs, 0.41 with anti-TNF alone, 0.54 with a thiopurine alone, and 0.95 with the two combined (Lemaitre 2017). Those are small absolute numbers, and combination therapy carried the most risk. In UNIFI, through 52 weeks, seven cancers (three non-melanoma skin cancers) occurred among 825 people on ustekinumab versus one among 319 on placebo (Sands 2019); the authors did not claim causation, and the follow-up was short.
Longer-term safety. The open-label vedolizumab study followed 894 people with UC for a median of 42.4 months (up to 8 years of data). It found no new trends for infections or malignancies and no cases of progressive multifocal leukoencephalopathy (PML). Serious adverse events were reported in 31% of UC patients, and 15% stopped the drug because of adverse events (Loftus 2020).
What the labels say. The US infliximab label has a boxed warning for serious infections, including tuberculosis and invasive fungal infections, and for lymphoma and other malignancies, including rare fatal hepatosplenic T-cell lymphoma, mostly in adolescent and young adult males who were also on azathioprine or 6-mercaptopurine (DailyMed, Remicade). The vedolizumab label lists infusion-related and hypersensitivity reactions, infections, liver injury, and says a risk of PML cannot be ruled out (DailyMed, Entyvio). The ustekinumab label says it may increase the risk of infections and malignancy (DailyMed, Stelara).
Reactions. A minority in r/UlcerativeColitis report serious reactions, including sepsis, a pulmonary embolism, anaphylaxis and throat tightening, in a thread about why people hesitate (Why the hesitation on biologics?). Those accounts are anecdotes and we cannot verify which drug caused what, but they match what the labels describe, which is why infusion centers monitor reactions and why you should report a rash, breathing trouble or swelling at once.
What checks come before starting a biologic?
Prescribers screen for infections that biologics can wake up and for vaccination gaps before the first dose. US labels call for tuberculosis testing before infliximab and ustekinumab, and hepatitis B testing before infliximab. Vedolizumab's label says to bring all immunizations up to date first. Ask your team for the exact checklist.
In practice, expect blood tests (and sometimes a chest X-ray or stool test), plus a conversation about past infections, travel, vaccines, and any history of cancer. The infliximab label says patients should be tested for latent tuberculosis before and during therapy, and tested for hepatitis B before starting (DailyMed, Remicade). The ustekinumab label asks for tuberculosis evaluation before the first dose and advises avoiding live vaccines during treatment (DailyMed, Stelara). Vedolizumab's label says all patients should be brought up to date with immunizations before starting (DailyMed, Entyvio).
Monitoring continues afterwards, which is the subject of why you need blood tests on a biologic. Call your team promptly if you develop a fever, persistent cough, a skin infection or unexplained weight loss on treatment. These are exactly the symptoms the screening and monitoring are designed to catch.
What does uncontrolled ulcerative colitis cost you?
It costs you in steroid exposure, hospital stays, surgery risk, quality of life and, over decades, a higher colorectal cancer risk. Staying on a weaker plan is not the "safe" default, because active inflammation has measurable harms of its own. The honest comparison is risk of treatment against risk of uncontrolled disease, not risk against zero.
Pulling the numbers from earlier sections together:
- Steroids. One year after a first steroid course, 22% of people with UC in the Minnesota cohort were steroid dependent (Faubion 2001).
- Hospitals. Hospitalizations for UC ran at 40 per 100 patient-years on placebo versus 20 on infliximab in ACT (Sandborn 2009).
- Surgery. Roughly 27% of people hospitalized with a severe attack needed colectomy in the short term (Turner 2007).
- Cancer. In a meta-analysis of population-based cohorts, UC raised the risk of colorectal cancer 2.4-fold, with a pooled standardized incidence ratio of 4.8 for extensive colitis and 1.6% of patients diagnosed over 14 years of follow-up (Jess 2012). That paper does not show that any medicine lowers this risk, so it is a reason to keep up surveillance colonoscopies whatever you take, not an argument for any one drug.
- Money. Costs vary hugely by country and plan. We publish no prices, and in the US a biologic can mean a prior authorization and a copay card conversation. How to afford ulcerative colitis medication covers programs, appeals and what to ask the pharmacy. Outside the US, access depends on national appraisals and local funding, so ask your IBD team what applies where you live.
If you are in remission with no medication and wondering whether you ever needed any, can you live without UC medication looks at what the relapse data show. And if your disease is mild and you are asking whether a biologic is overkill, the same logic is examined for Crohn's in should you start biologics for mild Crohn's, which is a useful comparison even though the conditions differ.
How do you decide if a biologic is worth it for you?
Decisions are usually made on disease severity, steroid use, prior treatment response and risk tolerance, not on the drug's reputation. The table below shows the factors that guidelines and trial designs lean on. It is a way to organize your questions for your gastroenterologist, not a checklist that produces an answer.
| Question | Why it matters | What to ask |
|---|---|---|
| How active is my UC, measured objectively? | Biologic trials enrolled moderate to severe disease; STRIDE-II targets endoscopic and biomarker control (Turner 2021) | "Do my calprotectin, bloods or scope confirm active inflammation?" |
| Have I needed steroids, and how often? | Steroid dependence and repeated courses are a common trigger for escalation | "Does my steroid use change what you would suggest?" |
| What have I already tried? | Prior anti-TNF exposure lowers response in some trials (Sandborn 2012) | "Does my history change which class suits me?" |
| What infection and vaccine history do I have? | Screening and vaccines come first | "What tests and shots do I need before starting?" |
| What is my personal risk picture? | Age, other conditions, previous cancer and pregnancy plans change risk | "What do the risks look like for someone like me?" |
| What will it cost, and who approves it? | Prior authorization and coverage shape what is practical | "Who handles the prior authorization and what is the backup plan?" |
Some people choose to wait and track. If you and your doctor agree to a trial of continuing a current plan, the evidence you will want is objective, not just how you feel. That means days with blood, stool frequency, urgency, night-time bowel movements, steroid courses and calprotectin, which together show whether your current treatment is controlling the disease. See the PRO-2 score for a standard way to score the first two. A simple log is enough, and some people use an app; Clairop can log these and turn them into a one-page report for appointments. It is patient-entered and does not interpret anything, and a paper diary does the same job.
Why do people hesitate, and why do some regret it?
People hesitate mainly because of the phrase "immune suppression" and because drug adverts read out long side-effect lists. People regret it mostly when the drug did not work for them. Many more describe regretting waiting too long on weaker treatment. These experiences coexist, and the trial data explain why: response rates are high enough to change lives and low enough that some people get nothing.
In the "Why the hesitation on biologics?" thread (88 comments), people describe a mental block about starting, fear of side-effect lists and the sense of losing the hope that the disease would go away by itself, and several say that once they started they wished they had done it years earlier (thread). One person in that thread describes being on mesalamine alone for years and being effectively housebound. Another describes a flare after years of remission on mesalamine and then agreeing to a switch without hesitation. These are personal accounts, and some commenters push back on "fear-mongering" while others describe real harm, so treat the tone of the thread with caution too.
The fair summary is that both groups are telling the truth. A biologic that works can be transformative, one that does not work is a cost without benefit, and a rare serious reaction is a harm that matters. That is why guidelines describe tiers of efficacy and why the decision belongs in a conversation about your numbers.
What if the first biologic doesn't work?
It is common enough that guidelines plan for it. Some people do not respond, and some lose response after months or years. The AGA gives separate suggestions for people who have been exposed to advanced therapies before, favoring higher or intermediate efficacy options, so another drug is a normal next step (Singh 2024).
Before deciding a drug has failed, doctors typically check drug levels, confirm that inflammation is still active, and rule out infection and missed doses. Our guide to when a biologic stops working covers those four causes and what usually happens next. The Reddit threads show the same pattern: several people describe losing response after years and switching to another class with good results, and others describe cycling through several drugs before one worked.
When should you call a doctor instead of waiting?
Call your IBD team promptly if you notice more frequent bloody stools, fever, severe abdominal pain, or any sign of infection on treatment. Seek urgent care for more than six bloody stools a day, a fast heartbeat, vomiting, dizziness, swelling of the abdomen or being unable to keep fluids down.
Also report an infusion reaction, new rash, breathing trouble, a persistent cough, yellowing of the skin or eyes, or new neurological symptoms (weakness, vision change, confusion) straight away, because those are the signals that labels tell prescribers to watch. If you are scheduled for a biologic and feel unwell with an infection, tell the team before the appointment, because the vedolizumab label says treatment should not be started in someone with a clinically important active infection until it resolves (DailyMed, Entyvio).
Do not stop, delay or change a biologic on your own because of something you read here or in a thread. The right response to a worry is a call to your team.
What should you bring to a biologic appointment?
Bring objective records, not just impressions: a short, specific list gets a better conversation than "are biologics worth it?" Bring your last three months of symptoms (days with blood, stool count, night-time episodes), any steroid courses with dates, calprotectin or scope results, every UC drug you have tried and how it went, and your vaccine history. Then ask the questions in the table above.
Three more questions are worth asking out loud. What does "working" look like for me, and by when will we judge it? What is the plan if it does not work? And what would make you stop it? The answers define a trial, so that "worth it" becomes something you can check against objective measures rather than a feeling. Our apps for ulcerative colitis list compares tracking options if you want one.
So, are biologics worth it for ulcerative colitis?
Biologics are not magic and they are not poison. For people with moderate to severe UC, they are the treatment the AGA recommends over no treatment, they raise remission rates and reduce hospital use and colectomy in trials, and they improve quality of life in people who respond. They also carry labeled infection and cancer warnings, they do not work for everyone, and some people cannot tolerate them. Uncontrolled UC is not a risk-free alternative.
Whether they are worth it for you is the sum of your disease activity, your history, your risks and your priorities. Use the numbers here to prepare questions, not to decide. If you are weighing it right now, the most useful step is a candid appointment with data in hand. If medicines keep failing, should I get my colon removed for ulcerative colitis? explains how surgery compares and what guidelines say about timing.




